FDA Approves Samsung Bioepis’ First Oncology Biosimilar Trastuzumab-dttb

The U.S. Food and Drug Administration (FDA) has approved trastuzumab-dttb (Ontruzant®; Samsung Bioepis) a biosimilar referencing* trastuzumab (Herceptin®; Genentech/Roche), for adjuvant treatment of HER2-overexpressing (ER/PR-negative o with high risk**) breast cancer, metastatic breast cancer and metastatic gastric cancer or gastroesophageal junction adenocarcinoma in patients who have not received prior treatment for metastatic disease. The agent is Samsung Bioepis’ first oncology...

Financial Toxicity: Privately Insured Cancer Survivors Carry Greater Medical Debt

Younger cancer survivors have are facing significant hardship as a result of their cancer treatment. A recent study also shows that cancer survivors in general carry greater financial burdens  - also referred to as financial toxicity - related to medical debt payments and bills compared with individuals without a cancer history. The result from the study, published online in CANCER,...

Trifluridine/tipiracil Significantly Improved Overall Survival versus Placebo in Gastric Cancer

The safety and efficacy of trifluridine/tipiracil (Lonsurf®; Taiho Oncology/Taiho Pharmaceutical and Servier) in patients who had undergone gastrectomy, the surgical removal of a part or the whole of the stomach, as part of their treatment for metastatic gastric cancer (mGC), are consistent with the overall study results published in The Lancet Oncology. Lonsurf® consists of a thymidine-based nucleoside analog, trifluridine,...

FDA Accepts sBLA for Atezolizumab + Abraxane and Carboplatin for Metastatic Non-squamous NSCLC

The United States Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for atezolizumab (Tecentriq®; Roche/Genentech) in combination with albumin-bound paclitaxel or nab-paclitaxel (Abraxane®; Abraxis Bioscience/Celgene) and carboplatin (Pfizer/Hospira) for the initial, first-line, treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumor aberrations. Atezolizumab is...

Neoleukin-2/15 – A Novel Immunotherapy Agent Designed to Avoid Common Side Effects

Scientists at the University of Washington Medicine's Institute for Protein Design (IPD) in Seattle, Washington, have created a new protein that mimics the action of a key immune regulatory protein, interleukin 2 (IL-2). In the development of the new protein, the scientists used a de novo computational approach for designing proteins that recapitulate the binding sites of natural cytokines, but...

Comparison of State-by-State Data Shows Melanoma Survival Varies Regionally

Cancer of the skin is by far the most common of all cancers and while melanoma accounts for only about 1% of all skin cancers, it causes a large majority of skin cancer deaths. According to data from the American Cancer Society, melanoma is more than 20 times more common in whites than in African Americans. Furthermore, the overall, lifetime,...

Study Confirms Complication Rates and Costs for Drugs and Diagnostics Higher in Lung Cancer

According to a new study from The University of Texas MD Anderson Cancer Center, complication rates following invasive diagnostic procedures for lung abnormalities were twice as high in the community setting compared to those reported in lung cancer screening trials. The procedures were also associated downstream average costs ranging from U.S. $ 6,320 to U.S. $ 56,845. In the study,...

Lonza and Takeda Bring Cancer Treatment to Patients

European Commission has approved brigatinib (Alunbrig®; Takeda), a once-daily tablet for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib (Xalkori®; Pfizer). To help develop the novel drug, scientists at Lonza Pharma & Biotech’s integrated product development and manufacturing facility in...

Amid Controversy AstraZeneca Appoints José Baselga to Head R&D for Oncology

In a rather surprising move, AstraZeneca has appointed José Baselga, MD, Ph.D, to head the company's Research & Development unit for Oncology. The appointment ends speculation of what Balsega would do after he resigned from his position as physician-in-chief and chief medical officer of Memorial Sloan Kettering Cancer Center, less than a week after The New York Times and ProPublica...

Tailoring Treatment to Men or Women with Glioblastoma May Improve Survival

A new study by researchers at the Washington University School of Medicine in St. Louis suggest that tailoring treatments to men and women with glioblastoma, based on the molecular subtypes of their tumors, may help improve survival. The study, supported by National Institutes of Health (NIH),  the Children’s Discovery Institute of Washington University, Joshua’s Great Things, the James S. McDonnell...

right side

ads

Related articles